The European Osteosarcoma Intergroup (E.O.I.) studies 1980–1991

  • A. W. Craft
  • J. M. V. Burgers
Part of the Cancer Treatment and Research book series (CTAR, volume 62)


In 1980 there was considerable confusion surrounding the management of osteosarcoma. Those involved in the management of this disease were faced with a series of conflicts. The early promise of chemotherapy as initially reported by Jaffe appeared to have been logically extended by Rosen in a series of studies culminating in the startling results of T10 wherein over 90% of patients were disease free at 2 years. However, the use of chemotherapy in Europe was producing surprisingly little improvement in survival over that achieved by amputation alone. Both the E.O.R.T.C. Studies and that undertaken by the Medical Research Council (M.R.C.) in the United Kingdom were disappointing, although in retrospect it is clear that the intensity of chemotherapy was inadequate [1,2]. At the same time the Mayo Clinic was reporting a survival of 50% with surgery alone and no chemotherapy, one of their explanations being that the natural history of the disease had changed and that chemotherapy was no longer necessary [3].


Clin Oncol Medical Research Council Cancer Study Group Study Scheme Considerable Confusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Medical Research Council (MRC). A trial of chemotherapy in patients with osteosarcoma (a report to the Medical Research Council by their Working Party on Bone Sarcoma). Br J Cancer 53:513–518, 1986.CrossRefGoogle Scholar
  2. 2.
    Burgers JMV, Van Glabbeke M, Busson A, et al. Osteosarcoma of the limbs: report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation. Cancer 5:1024–1031, 1988.CrossRefGoogle Scholar
  3. 3.
    Edmondson JH, Green SJ, Ivins JC, et al. A controlled pilot study of high-dose methotrexate: a postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 2:156, 1984.Google Scholar
  4. 4.
    Link MP. Adjuvant therapy in the treatment of osteosarcoma. In: Important Advances in Oncology. De Vita VT, Helson S, Rosenberg SA, Eds. Lippincott, Philadelphia, J.B. 1986, pp 193–207.Google Scholar
  5. 5.
    Eilber F, Giuliano A, Edkardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomised prospective trial. J Clin Oncol 5:21–26, 1987.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • A. W. Craft
    • 1
  • J. M. V. Burgers
    • 2
  1. 1.The Royal Victoria InfirmaryNewcastle Upon TyneUnited Kingdom
  2. 2.The Netherlands Cancer InstituteAmsterdamThe Netherlands

Personalised recommendations